The primary purposes of this study are to:
•Provide access to cord blood units for recipients whose best choice for a cord blood unit(s) do not meet all FDA standards, but do meet standards set by the NMDP on this study.
•Assess how well and how quickly blood counts return to normal after transplant in recipients on this study.

This study is being offerred to patients that have acute myelogenous leukemia (AML) which is a cancer of the blood and these patients are going to have a stem cell transplant. This study is looking to determine how accurate two different laboratory tests are at detecting residual, or small numbers of cancer cells in the body before and after stem cell transplant, as well as whether or not results of these two tests show how well a recipient might do after transplant.

This study if for patients that have a blood disease and it's been determined that the best option for treating that blood disease is a cord blood transplant. Cord blood (CB) is blood that is taken from the umbilical cord and placenta of healthy newborn babies after childbirth. The cord blood collected from a newborn baby is called a cord blood unit. The United States Food and Drug Administration (FDA) considers cord blood to be a biological drug. These are considered “investigational” products. This study will evaluate the safety of administration of the investigational cord blood units by carefully documenting all infusion-related problems.

This is a clinical research study of an investigational new drug to treat relapsed/refractory multiple myeloma. The name of this investigational new drug is elotuzumab. The purpose of this study is to determine if elotuzumab given with bortezomib and dexamethasone is more effective in the treatment of relapsed or refractory multiple myeloma compared with a standard treatment of bortezomib and dexamethasone alone. This study will also assess the safety of elotuzumab given with bortezomib and dexamethasone compared with bortezomib and dexamethasone alone. This study will also measure how the body processes elotuzumab.

Screening tests will be done to determine that subjects are eligible for participation in the study. Subjects will be randomized to one of two treatment groups. One group will receive elotuzumab with dexamethasone and bortezomib. The other group will receive dexamethasone and bortezomib only. There will be optional genetic testing that subjects may or may not choose to participate in. It is not known how long participation in the study may last. Treatment will continue until the disease gets worse, subjects have unacceptable side effects, or the subject or their doctor decide it is in their best interest to withdraw from the study.

The primary purpose of this study is to determine the effects of ruxolitinib on spleen size and symptoms and to learn about any of the side effects that might occur during or following treatment. This study will also help us determine the appropriate dosing for patients with low platelets. To see if ruxolitinib is having any effect on your disease we will collect other blood samples called biomarker or, in this study, pharmacodynamic samples. During the screening phase, tests including blood draws, bone marrow biopsy, physical exam, MRI/CT as necessary, will be done to determine a patient's eligibility. The treatment phase consists of 24 weeks where patients will take the study drug and come to MUSC for tests including blood draws, physical exams, genetic testing etc to measure how the pt is responding to treatment. Subjects may continue to receive treatment after 24 weeks if their doctor agrees that this is appropriate.

This study is for subjects that have myelodysplastic syndrome (MDS) that may have caused an accumulation of abnormal cells called blasts, and this puts you at a high risk of developing leukemia.The purpose of this study is to determine how well a drug called ON 01910.Na works on people with MDS and to study the safety of ON 01910.Na when it is given to people with MDS. If the study doctor says that the subject can be in the study and the subject wants to be in the study, he or she will continue to get supportive care, also, the study doctor will give some people in the study ON 01910.Na with a needle over a period of 72 hours once every other week for 16 weeks, then once every 4 weeks over a period of 72 hours. There will be a screening period for each subject and can last up to 14 days. Subjects will then be randomized (like flipping a coin) to which study group they will be in. One group will get the study drug and one will not. Participation in this research study is expected to continue until disease progression or, for Group 1, subjects stop taking study drug.

This study is for subjects that have have been diagnosed as having advanced renal cell carcinoma that has been treated previously, but has not responded or got worse despite treatment. E7080 is an investigational drug that is in development for the treatment of cancer, including renal cell carcinoma. E7080 is thought to work by stopping the formation of new blood vessels that help cancer cells grow and spread. Everolimus is also used in this study and is a drug approved by the FDA and other Health Authorities for the treatment of advanced renal cell carcinoma. Subjects will either receive E7080, Everolimus or both drugs together. Also being studied is how your genetic make up affects how your body absorbs, distributes, breaks down and excretes the study drugs. There will be a screening visit to determine subjects eligibility and a baseline visit that will determine is subjects are still eligible to participate in this study. If subjects are eligible and choose to participate, then subjects will be assigned to one of three study groups. Each treatment cycle is 28 days long. Subjects are expected to be on this study for approximately 24 months or 2 years.

The research study will determine whether an investigational drug 99mTc-MIP-1404 is effective in detecting prostate cancer tissue within the prostate gland and elsewhere in your body when used with imaging techniques. This study will be for patients that will be undergoing a Radical Prostatectomy with extended pelvic lymph node dissection as treatment for prostate cancer. This is not a treatment based study.

This is a multi-center, 6000 subject validation study of several biomarkers for early detection of colon and/or rectal cancer. There are 2 stool based biomarkers (one is a panel) and 1 serum based biomarker being validated in this study. The biomarkers will be compared with colonoscopy and with FIT (fecal immunohistochemistry) tests which are the current standards for colon cancer screening.

The main purpose of this study is to examine the safety of the study drug in patients with locally advanced unresectable pancreatic adenocarcinoma. The study team would like to know about any side effects a patient may have when given the study drug. Another goal of the study is to determine if combining dendritic cells and the study drug can be possibly used as a vaccine for this disease. Dendritic cells are cells that are present in the body’s immune system that help your body fight disease.